Some of Massachusetts’ largest life sciences employers, as well as smaller biotechs, increased their headcount in 2024, ...

High-rolling investors have positioned themselves bullish on Biogen BIIB, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of ...

Cambridge-based biopharmaceutical company Sage Therapeutics filed a lawsuit against their partner, the biotechnology company Biogen, after rejecting their $469 million buy-out proposal late last ...

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...

Biogen's strategic missteps, including the failed Sage Therapeutics acquisition, underscore a lack of innovation and direction, leading to a "sell" rating. Despite being forewarned, Wall Street ...

Sage Therapeutics has left its view of Biogen's recent takeover bid in little doubt – it has just filed a lawsuit seeking to block the deal. Specific details of the lawsuit are not yet available ...

TD Cowen 45th Annual Health Care Conference March 3, 2025 9:10 AM ETCompany ParticipantsChris Viehbacher - CEOConference ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

Sage Therapeutics and partner Biogen equally shares profits and losses for the commercialization of Zurzuvae in the United States. In ex-U.S. markets, Biogen records product sales (excluding Japan ...

Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and ...

Canaccord said they will continue to keep a close watch on Zurzuvae’s performance given partner Biogen’s (BIIB) unsolicited takeover approach, which Sage has decided not to accept, and Sage ...